Translational research: Walking the bridge between idea and cure - Seventeenth Bruce F. Cain memorial award lecture

Cancer Research

Volumn 58, Issue 19, 1998, Pages 4211-4216

  Chabner, Bruce A ^a   Boral, Anthony L ^a   Multani, Pratik ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CANCER RESEARCH; CLINICAL RESEARCH; DNA REPAIR; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GENETIC TECHNIQUES; HUMANS; NEOPLASMS; RESEARCH;

EID: 0032188838     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Graham, M. A., and Workman, P. The impact of pharmacokinetically-guided dose escalation strategies in Phase I clinical trials: critical evaluation and recommendations for future studies. Ann. Oncol., 3: 339-347, 1992.
2. De Azevedo, W. F., Jr., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., and Kim, S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA., 93: 2735-2740, 1996.
3. Chabner, B. A., Allegra, C. J., Curt, G. A., Clendeninn, N. J., Baram, J., Koizumi, S., Drake, J. C., and Jolivet, J. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest., 76: 907-912, 1985.
4. Decoster, G., Stein, G., and Holdener, E. E. Responses and toxic deaths in Phase J clinical trials. Ann. Oncol., 1: 175-181, 1990.
5. Zukerberg, L. R., Nickoloff, B. J., and Weiss, S. W. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis. Am. J. Surg, Pathol., 17: 321-328, 1993.
6. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
7. Yuan, F., Chen, Y., Dellian. M., Safabakhsh, N., Ferrara, N., and Jain, R. K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA., 93: 14765-14770, 1996.
8. Bordron, A., Dueymes, M., Levy, Y., Jamin, C., Leroy, J. P., Piette. J. C., Shoenfeld, Y., and Youinou, P. Y. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J. Clin. Invest., 101: 2029-2035, 1998.
9. Arap, W., Pasqualini, R., and Ruoslahti, E. Cancer treatment by targeted drag delivery to tumor vasculature in a mouse model. Science (Washington DC), 279: 377-380, 1998.
10. Klagsbrun, M., and Pa, D. A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev., 7: 259-270, 1996.
11. Findlay, M. P., and Leach, M. O. In vivo monitoring of fluoropyrimidine metabolites: magnetic resonance spectroscopy in the evaluation of 5-fluorouracil. Anticancer Drugs, 5: 260-280, 1994.
12. Mishima, Y., Imahori, Y., Honda, C., Hiratsuka, J., Ueda, S., and Ido, T. In vivo diagnosis of human malignant melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue. J. Neurooncol., 33: 163-169, 1997.
13. Huang, S. C., Phelps, M. E., Huffman, E. J., and Kuhl, D. E. A theoretical study of quantitative flow measurements with constant infusion of short-lived isotopes. Phys. Med. Biol., 24: 1151-1161, 1979.
14. Coleman, R. E., and Sostman, H. D. Technology for functional and metabolic imaging. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, pp. 673-682. Philadelphia: Lippincott-Raven Publishers, 1997.
15. Moasser, M. M., Sepp-Lorenzino, L., Kohl, N. E., Oliff, A., Balog, A., Su, D. S., Danishefsky, S. J., and Rosen, N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to Taxol and epothilones. Proc. Natl. Acad. Sci. USA., 95: 1369-1374, 1998.
16. Bible, K. C., and Kaufmann, S. H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996.
17. Pietras, R. J., Fendly, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., and Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829-1838, 1994.
18. Baselga, J., Norton, L., Albanell, J., Kim, Y-M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxonibicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
19. Crookc, S. T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol., 32: 329-376, 1992.
20. Holmlund, J., Nemunaitis, J., Schiller, J., Dorr, A., and Kisner, D. Phase I trial of C-raf antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 17: 811a, 1998.
21. Sikic, B. I., Yuen, A. R., Advani, R., Halsey, J., Fisher, G. A., Holmlund, J., and Dorr, A. Antisense oligonucleotide therapy targeted to protein kinase C-a (ISIS 3521/CGP 64128A) by 21 day infusion: results of the Phase 1 trial and activity in ovarian carcinomas. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 17: 1654a, 1998.
22. Szczylik, C., Skorski, T., Nicolaides, N. C., Manzella, L., Malaguarnera, L., Venturelli, D., Gewirtz, A. M., and Calabretta, B. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science (Washington DC), 253: 562-565, 1991.
23. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefane, F., Ross, P., Corbo, M., and Dziewanowska, Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 1137-1141, 1997.
24. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med., 2: 668-675, 1996.
25. Dean, N., McKay, R., Miraglia, L., Howard, R., Cooper, S., Giddings, J., Nicklin, P., Meister, L., Ziel, R., Geiger, T., Muller, M., and Fabbro, D. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res., 56: 3499-3507, 1996.
26. O'Dwyer, P. J., Stevenson, J. P., Gallagher, M., Mitchell, E., Friedland, D., Rose, L., Cassella, A., Holmlund, J., Dean, N., Dorr, A., Geary, R., and Yao, K-S. Phase I/pharmacokinetic/pharmacodynamic trial of Raf-1 amisense ODN (ISIS 5132, CGP 69846A). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 17: 810a, 1998.
27. Hunter, T. Oncoprotein networks. Cell, 88: 333-346, 1997.
28. Workman, P., Brunton, V. G., and Robins, D. J. Discovery and design of inhibitors of oncogenic tyrosine kinases. In: P. Workman (ed.). New Approaches in Cancer Pharmacology: Drug Design and Development, Vol. 2. pp. 55-70. New York: Springer-Verlag, 1994.
29. Monia, B. P., Sasmor, H., Johnston, J. F., Freier, S. M., Lesnik, E. A., Muller, M., Geiger, T., Altmann, K. H., Moser, H., and Fabbro, D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA., 93: 15481-15484, 1996.
30. Boyle, C. C., and Hickman, J. A. Toxin-induced increase in survival factor receptors: modulation of the threshold for apoptosis. Cancer Res., 57: 2404-2409, 1997.
31. Dunn, S. E., Hardman, R. A., Kari, F. W., and Barrett, J. C. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res., 57: 2687-2693, 1997.
32. Slamon, D., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Woher, J., Baselga, J., and Norton, L. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for her2 overexpression metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 17: 377a, 1998.
33. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., Jr., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993.
34. Rasouli-Nia, A,. Liu, D., Perdue, S., and Britten, R. A. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. Clin. Cancer Res., 4: 1111-1116, 1998.
35. Lipson, K. E., Wang, X., Chen, H., Chu, L., Nematalla, A., Tang, C., Strawn, L. M., Shawver, L. K., Hirth, K. P., and McMahon, G. SU101, and not its major metabolite, inhibits PDGF-dependent cell growth. Proc. Am. Assoc. Cancer Res. Annu. Meet., 39: 558-559, 1998.
36. Thompson, A. M., Murray, D. K., Elliott, W. L., Fry, D. W., Nelson, J. A., Showalter, H. D., Roberts, B. J., Vincent, P. W., and Denny, W. A. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl) amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem., 40: 3915-3925, 1997.
37. Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., and Druker, B. J. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL. TEL-ABL, and TEL-PDGFR fusion proteins. Blood, 90: 4947-4952, 1997.
38. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
39. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
40. Wilson, W. H., Teruya-Feldstem, J., Fest, T., Harris, C., Steinberg, S. M., Jaffe, E. S., and Raffeid, M. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood, 89: 601-609, 1997.
41. Iwadate, Y., Tagawa, M., Fujimoto, S., Hirose, M., Namba, H., Sueyoshi, K., Sakiyama, S., and Yamaura, A. Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. Br. J. Cancer, 77: 547-551, 1998.
42. Spitz, F. R., Nguyen, D., Skibber, J. M., Cusack, J., Roth, J. A., and Cristiano, R. J. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res., 16: 3415-3422, 1996.
43. Chu, E., and Allegra, C. J. The role of thymidylate synthase in cellular regulation. Adv. Enzyme Regul., 36: 143-163, 1996.
44. Li, Y., and Benezra, R. Identification of a human mitotic checkpoint gene: hsMAD2. Science (Washington DC), 274: 246-248, 1996.
45. Shao, R-G., Cao, C-X., Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res., 57: 4029-4035, 1997.
46. Hunault, M., Zhou, D., Delmer, A., Ramond, S., Viguie, P., Cadiou, M., Perrot, J. Y., Levy, V., Rio, B., Cymbalista, F., Zittoun, R., and Marie, J. P. Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment Ann. Hematol., 74: 65-71, 1997.
47. Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I. M., Head, D. R., Appelbaum, F. R., and William, C. L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 89: 3323-3329, 1997.
48. Leighton, J. C., Jr., and Goldstein, L. J. P-glycoprotein in adult solid tumors. Expression and prognostic significance. Hematol. Oncol. Clin. N. Am., 9: 251-273, 1995.
49. Linn, S. C., and Giaccone, G. MDR1/P-glycoprotein expression in colorectal cancer. Eur. J. Cancer, 31A: 1291-1294, 1995.
50. Verrelle, P., Meissonnier, F., Fonck, Y., Feillel, V., Dionet, C. Kwiatkowski, F., Plagne, R., and Chassagne, J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J. Natl. Cancer Inst., 83: 111-116, 1991.
51. Khalifa, M. A., Abdoh, A. A., Mannel, R. S., Walker, J. L., Angros, L. H., and Min, K. W. P-glycoprotein as a prognostic indicator in pre- and postchemotherapy ovarian adenocarcinoma. Int. J. Gynecol. Pathol., 16: 69-75, 1997.
52. Serra, M., Scotlandi, K., Manara, M. C., Maurici, D., Benini, S., Sarti, M., Nini, G., Barbanti-Brodano, G., and Baldini, N. Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities. Cytotechnology, 19: 253-256, 1996.
53. Scotlandi, K., Serra, M., Nicoletti, G., Vaccari, M., Manara, M. C., Nini, G., Landuzzi, L., Colacci, A., Bacci, G., Bertoni, F., Picci, P., Campanacci, M., and Baldini, N. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res., 56: 2434-2439, 1996.
54. List, A. F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher. B., Baier, M., and Dalton, W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol., 11: 1652-1660, 1993.
55. Toffoli, G., Sorio, R., Gigante, M., Corona, G., Galligioni, E., and Boiocchi, M. Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide. Br. J. Cancer. 75: 715-721, 1997.
56. Sonneveld, P., Suciu, S., Weijermans, P., Beksac. M., Neuwirtova, R., Solbu, G., Lokhorst, H., van der Lelie, J., Dohner, H., Gerhartz, H., Segeren, C. M., Willemze, R., and Löwenberg, B. Cyclosporin A combined with VAD versus VAD in patients with refractory multiple myeloma: an EORTC/HOVON randomized Phase II study. Blood. 90 (Suppl. 1): 356a, 1997.
57. Tolcher, A. W., Cowan, K. H., Solomon, D., Ognibene, F., Goldspiel, B., Chang, R., Noone, M. H., Denicoff, A. M., Barnes, C. S., Gossard, M. R., Fetsch, P. A., Berg, S. L., Balis, F. M., Venzon, D. J., and O'Shaughnessy, J. A. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J. Clin. Oncol., 14: 1173-1184, 1996.
58. Wilson, W. H., Bates, S. E., Fojo, A., Bryant, G., Zhan, Z., Regis, J., Wittes, R. E., Jaffe, E. S., Steinberg, S. M., Herdt, J., and Chabner, B. A. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J. Clin. Oncol., 13: 1995-2004, 1995.
59. Dalton, W. S., Crowley, J. J., Salmon, S. S., Grogan, T. M., Laufman, L. R., Weiss, G. R., and Bonnet, J. D. A Phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer (Phila.), 75: 815-820, 1995.
60. Sonneveld, P., Marie, J. P., Huisman, C., Vekhoff, A., Schoester, M., Faussat, A. M., van Kapel, J., Groenewegen, A., Charnick, S., Zittoun, R., and Lowenberg, B. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A Phase I study. Leukemia (Baltimore), 10: 1741-1750, 1996.
61. Peck, R. A., Marshall, J., Ziessman, H., Hewetl, J., Schmalbach, T., Chaturvedi, P., and Hawkins, M. A phase I trial of doxorubicin and VX-710. Proc. Am. Assoc. Cancer Res. Annu. Meet., 37: 165, 1996.
62. Kornblau, S. M., Estey, E., Madden, T., Tran, H. T., Zhao, S., Consoli, U., Snell, V., Sanchez-Williams, G., Kantarjian, H., Keating, M., Newman, R. A., and Andreeff, M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J. Clin. Oncol., 15: 1796-1802, 1997.
63. Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J., Juijn, J. A., Baas, F., and Borst, P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res., 57: 3537-3547, 1997.
64. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., and Ross, D. D. Characterization of transfectants of breast cancer resistance protein (BCRP), a novel ATP-binding cassette (ABC) transporter that contributes to the multidrug-resistance phenotype of MCF-7/ADRVP breast cancer cells. Proc. Am. Soc. Clin. Oncol., 17: A769, 1998.
65. Duan, Z., Feller, A., Foh, H. C., and Seiden, M. V. The identification of a novel gene from a Taxol resistant ovarian carcinoma cell line. Am. Assoc. Cancer Res. Annu. Meet., 39: 685, 1998.
66. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., and Wilkinson, G. R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 101: 289-294, 1998.